back to top
- Targeting a Myeloma Translocation for the First Time: The t(11;14) JourneyJune 26, 2018 | July-August 2018, Volume 15, Issue 4
Drs. Sklavenitis Pistofidis and Ghobrial discuss a study that looks at a targeted approach to therapy for multiple myeloma patients carrying a t(1;14) translocation.
- When Does Monoclonal Gammopathy Acquire Significance?February 08, 2018 | March-April 2018, Volume 15, Issue 2
Drs. Bustoros, Liu, Sklavenitis-Pistofidis, and Ghobrial look at studies by Dr. Robert Kyle that have transformed the landscape of precursor conditions is plasma cell malignancies and cancer, specifically the understanding of MGUS.
Dr. Sklavenitis Pistofidis is a Postdoctoral Fellow in the Department of Medical Oncology at Dana-Farber Cancer Institute/Harvard Medical School. His main research interest is plasma cell dyscrasias.
Dana-Farber Cancer Institute/Harvard Medical School